Enkephalin degrading enzymes: Metalloproteases with high potential for drug development

Current Pharmaceutical Design

Volumn 18, Issue 2, 2012, Pages 220-230

  Khaket, Tejinder Pal ^a   Singh, Jasbir ^a   Attri, Pooja ^a   Dhanda, Suman ^a  

^a KURUKSHETRA UNIVERSITY   (India)

Author keywords

Aminopeptidase N; Angiotensin converting enzyme; Carboxypeptidase A6 and pain; Dipeptidylpeptidase III; Enkephalins; Neutral endopeptidase; Puromycin sensitive enzyme

Indexed keywords

2,9 DIMETHYL 1,10 PHENANTHROLINE; ACETORPHAN; ACTINONIN; AMASTATIN; ATRIAL NATRIURETIC FACTOR; BESTATIN; BESTATIN DERIVATIVE; CANDOXATRIL; CANDOXATRILAT; CHELATING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; EDETIC ACID; EGTAZIC ACID; ENKEPHALIN; ENKEPHALIN DEGRADING ENZYME; ENKEPHALIN DEGRADING ENZYME INHIBITOR; ENZYME INHIBITOR; ILOMASTAT; MEMBRANE METALLOENDOPEPTIDASE; METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; N [1 [(2,2 DIMETHYL 1,3 DIOXOLAN 4 YL)METHOXYCARBONYL] 2 PHENYLETHYL]PHENYLALANYL BETA ALANINE; N [2 (ACETYLTHIOMETHYL) 3 (2 METHYLPHENYL)PROPIONYL]METHIONINE ETHYL ESTER; PROCTOLIN; PUROMYCIN; SINORPHAN; TAU PROTEIN; THIOL DERIVATIVE; THIORPHAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANALGESIA; ANALGESIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; CANCER PAIN; CELL CYCLE REGULATION; DIARRHEA; DRUG BIOAVAILABILITY; ENZYME INHIBITION; ENZYME STRUCTURE; HORMONE METABOLISM; HUMAN; HYPERTENSION; IC 50; IMMUNOREGULATION; INFLAMMATION; NEUROPATHIC PAIN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW;

AMINOPEPTIDASES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENKEPHALINS; HUMANS; NEOPLASMS; NEURALGIA;

EID: 84856424923     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799040547     Document Type: Review

References (102)

1. Chen H, Noble F, Coric P, Fournie-Zaluski MC, Roques BP. Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics. Proc Natl Acad Sci USA 1998; 95: 12028-12033.
2. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87-146.
3. Dudas B and Merchenthaler I. Topography and associations of leuenkephalin and luteinizing hormone-releasing hormone neuronal systems in the human diencephalon. J Clin Endo Met 2003; 88(4): 1842-48.
4. Owczarek D, Garlicka M, Pierzchala-Koziec K, Skulina D, Szulewski P. Met-enkephalin plasma concentration and content in liver tissue in patients with primary biliary cirrhosis. Przegl. Lek 2003; 60(7): 461-66.
5. 2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem 2003; 278: 12729-36.
6. Gordana P, Zorica J, Karin V, Sneana C, Svetlana A. Immunomodulatory activity of methionine-enkephalin, leucine-enkephalin, inhibitors of enkephalin degrading enzymes and releasing" dipeptide after intracerebroventricular administration in rats. Acta fac Med Naiss 2004; 21(4): 185-194.
7. Gorenstein C, Snyder SH. Enkephalinases. Proc R Soc Lond B Biol Sci 1980; 120(1178): 123-132.
8. Karsten SL, Sang TK, Gehman LT et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron; 2006; 51: 549-560.
9. Safavi, A and Hersh LB. Degradation of dynorphinrelated peptides by the puromycin-sensitive aminopeptidase and aminopeptidase M. J Neurochem 1995; 65: 389-395.
10. Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, Fontana A. Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. J Biol Chem 1995; 270: 26931-26939.
11. Sengupta S, Peleg M. Horowitz, Stanislav L et al. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 2006; 45: 15111-15119.
12. Hersh LB. Solubilization and characterization of two rat brain membrane-bound aminopeptidases active on met-enkephalin. Biochemistry 1981; 20: 2345-2350.
13. Hui KS. Brain-specific aminopeptidase: from enkephalinase to protector against neurodegeneration, Neurochem Res 2007; 32: 2062-2071.
14. Thompson MW, Tobler A, Fontana A, Hersh LB. Cloning and analysis of the gene for the human puromycin-sensitive aminopeptidase. Biochem Biophys Res Commun 1999; 258(2): 234-40.
15. Thompson MW, Govindaswami M, Hersh LB. Mutation of active site residues of the puromycin-sensitive aminopeptidase: conversion of the enzyme into a catalytically inactive binding protein. Arch Biochem Biophys 2003; 413: 236-242.
16. Saric T, Graef CI and Goldberg AL. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem 2004; 279: 46723-46732.
17. Osada T, Ikegami S, Takiguchi-Hayashi K et al. Increased anxiety and impaired pain response in puromycin-sensitive aminopeptidase gene-deficient mice obtained by a mouse gene-trap method. J Neurosci 1999; 19: 6068-6078.
18. Menzies FM, Hourez R, Imarisio S et al. Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy. Human Molecular Genetics 2010; 19(23):4573-86.
19. Komoda M, Kakuta H, Takahashi H et al. Specific inhibitor of puromycin-sensitive aminopeptidase with a homophthalimide skeleton: identification of the target molecule and a structureactivity relationship study. Bioorg Med Chem 2001; 9(1): 121-31.
20. Luan Y and Xu W. The structure and main functions of aminopeptidase N. Curr Med Chem 2007; 14: 639-647.
21. Luciani N, Marie-Claire C, Ruffet E, Beaumont A, Roques BP, Fournie-Zaluski MC. Characterization of glu350 as a critical residue involved in the n-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): Insights into Its Mechanism of Action. Biochemistry 1998; 37: 686-692.
22. Ward PE, Benter IF, Dick L, Wilk S. Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M. Biochem Pharmacol 1990; 40: 1725-1732.
23. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT. Kallidin-and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 1999; 99: 1984-1990.
24. Saiki I, Fujii H, Yoneda J, Nakajima M, Tsuruo T, Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J cancer 1993; 54: 137-143.
25. Delmas B, Gelfi J, Kut E, Sjostrom H, Noren O, Laude H. Determinants essential for the transmissible gastroenteritis virus-receptor interaction reside within a domain of aminopeptidase-N that is distinct from the enzymatic site. J Virol 1994; 68: 5216-5224.
26. Sjostrom H, Noren O, Olsen J. Structure and functions of aminopeptidase N. Adv Exp Med Biol 2000; 477: 25-34.
27. Toh H, Minami M, Shimizu T. Molecular evolution and zinc ion binding motif of leukotriene A4 hydrolase. Biochem Biophys Res Commun 1990; 171: 216-221.
28. Riemann D, Kehlen A, Langner J. CD13-not just a marker in leukemia typing. Immunol Today 1999; 20: 83-88.
29. Noble F, Roques BP. Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin Ther Targets 2007; 11: 145-159.
30. Danziger RS. Aminopeptidase N in arterial hypertension. Heart Fail Rev 2008; 13: 293-298.
31. Haraguchi N, Ishii H, Mimori K et al. MCD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 1; 120(9): 3326-39.
32. Gros C, Noel N, Souque A et al. Mixed inhibitors of angiotensinconverting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci U.S. A 1991; 88: 4210-4.
33. Antczak C, Radu C and Djaballah H. A Profiling Platform for the Identification of Selective Metalloprotease Inhibitors. J Biomol Screen 2008; 13(4): 285-294.
34. Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev 2005; 26: 88-130.
35. Grzywa R, Oleksyszyn J, Salvesen GS, Drag M. Identification of very potent inhibitor of human aminopeptidase N (CD13). Bioorg Med Chem Lett 2010; 15(20): 2497-9.
36. Maiereanu C, Schmitt C, Schifano-Faux N, Le Nouën D, Defoin A, Tarnus C. A novel amino-benzosuberone derivative is a picomolar inhibitor of mammalian aminopeptidase N/CD13. Bioorg Med Chem 2011;19(18): 5716-33.
37. Yang K, Fen J, Fang H, Zhang L, Gong J, Xu W. Synthesis of a novel series of L-isoserine derivatives as aminopeptidase N inhibitors. J Enzyme Inhib Med Chem 2011; doi:10.3109/14756361003698147
38. Li X, Wang J, Zhang L, Xu W. Design, synthesis, and preliminary activity evaluation of novel peptidomimetics as aminopeptidase N/CD13 inhibitors. Arch Pharm (Weinheim). 2011; 344(8): 494-504.
39. Su L, Fang H, Yang K, Xu Y, Xu W. Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors. Bioorg Med Chem. 2011; 19(2): 900-6.
40. Rao M, Li Q, Feng L, Xia X, Ruan L, Sheng X, Ge M. A new aminopeptidase inhibitor from Streptomyces strain HCCB10043 found by UPLC-MS. Anal Bioanal Chem 2011; 401(2): 699-706
41. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997; 11; 355-364.
42. Lee CM and Snyder SH. Dipeptidyl-aminopeptidase III of rat brain elective affinity for enkephalin and angiotensin. J Biol Chem 1982; 257; 12043-12050.
43. Waksman G, Hamel E, Delay-Goyet P, Roques BP. Neutral endopeptidase-24.11, μ and δ opioid receptors after selective brain lesions: an autoradiographic study. Brain Res 1987; 436: 205-216.
44. Matsas R, Fulcher IS, Kenny AJ and Turner AJ. Substance P and Leu-enkephalin are hydrolyzed by an enzyme in pig caudate synaptic membranes that is identical with the endopeptidase of kidney microvilli. Proc Natl Acad Sci USA 1983; 80; 3111-3115.
45. Oefner C, Bernard P, Roques BP, Fournie-Zaluski MC, Dale GE. Structural analysis of neprilysin with various specific and potent inhibitors. Acta Cryst 2004; D60: 392-396.
46. Iwata N, Tsubuki S, Takaki Y et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292: 1550-1552.
47. Malfroy B, Schofield PR, Kuang WJ, Seeburo PH, Mason AJ, Henzel WJ. Molecular cloning and amino acid sequence of rat enkephalinase. Biophys Res Commun 1987; 144: 59-66.
48. Moual HL, Devault A, Roques BP, Crine P and Boileau G. Identification of Glutamic Acid 646 as a Zinc-coordinating Residue in Endopeptidase-24.11. J Biol Chem 1991; 266; 24: 15670-15674.
49. Schwartz JC, Costentin J, Lecomte JM. Pharmacology of enkephalinase inhibitors. Trends Pharmacol Sd 1985; 6: 472-476.
50. Roques BP. Enkephalinase inhibitors and molecular exploration of the differences between active sites of enkephalinase and the angiotensin conversion enzyme. Pharmacol (Paris) 1985; 16: 5-31.
51. Chipkin RE, Berger JG, Billard W, Lorlo LC, Chapman R, Barnett A. Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. Pharmacol Exp Ther 1988; 245: 829-838.
52. Brandstetter H, Kuhne A, Bode W et al. X-ray structure of active site inhibited clotting factor Xa-Implications for drug design and substrate recognition. J Biol Chem 1996; 271: 29988-92.
53. Angelo J, Trapani, Beil ME et al. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats Clinical Science 2002; 103(48): 102S-106S.
54. Rougeot C, Messaoudi M, Hermitte V et al. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity. PNAS 2003; 100(14): 8549-8554.
55. Ellis S, Nuenke JM. Dipeptidyl arylamidase III of pituitary, purification and characterization. J Biol Chem 1967; 242(20): 4623-4629.
56. Zhan H, Yamamoto Y, Shmiya S et al. Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats. Histochem J 2001; 33(9-10): 511-521.
57. Dhanda S, Singh H, Singh J, Singh TP. Isolation, purification and characterization of a DPP-III homologue from goat brain. Protein Express Purif 2007; 52: 297-305.
58. Abramic M, Sagi D, Simaga S et al. Human and rat dipeptidyl peptidase III: biochemical and mass spectrometric arguments for similarities and differences. Biol Chem 2000; 381(12): 1233-1243.
59. Dhanda S, Singh H, Singh J, Singh TP. Functional characterization and specific effects of various peptides on enzymetic activity of DPP-III homologue from goat brain. J Enz Inh Med Chem 2008; 26(3): 174-81.
60. Dhanda Suman, Jasbir Singh, Singh Hari. Interaction of goat brain enkephalin degrading enzymes with analgesic and antihypertensive drugs. Med Chem Res 2011; 20(8): 1294-1297.
61. Smyth M, O'Cuinn G. Dipeptidyl aminopeptidase activities of guinea-pig brain. Int J Biochem; 1994; 26 (7): 913-921.
62. Barsun M, Jajcanin N, Vukelic B, Spoljaric J, Abramic M. Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. Biol. Chem 2007; 388(3): 343-348.
63. Abramic M, Simaga S, Osmak M et al. Highly reactive cysteine residues are part of the substrate binding site of mammalian dipeptidyl peptidases III. Int J Biochem Cell Biol 2004; 36(3): 434-446.
64. Fukasawa K, Fukasawa KM, Kanai M, Fujii S, Hirose J, Harada M. Dipeptidyl peptidase III is a zinc metallo-exopeptidase. Molecular cloning and expression. Biochem J 1998; 329: 275-282.
65. Baral PK, Nina J, Abramic M, Karl G, Peter M. The first structure of dipeptidyl-peptidase III provides insight into the catalytic mechanism and mode of substrate binding. J Biol Chem 2008; 283(32): 22316-22324.
66. Grdisa M, Vitale L. Types and localization of aminopeptidases in different human blood cells. Int J Biochem 1991; 23(3); 339-345.
67. Docherty K, Steiner DF. Post-translational proteolysis in polypeptide hormone biosynthesis. Annu Rev Physiol 1982; 44: 625-638.
68. Dhanda S, Singh H, Singh J. Hydrolysis of various bioactive peptides by goat brain dipeptidylpeptidase-III. Cell Biochem Funct 2008; 23(2): 339-45.
69. Akiyama T, Harada S, Kojima F et al. Fluostatins A and B, new inhibitors of dipeptidyl peptidase III, produced by Streptomyces sp. TA-3391. I. Taxonomy of producing strain, production, isolation, physico-chemical properties and biological properties. J Antibiot 1998; 51(6): 553-9.
70. Yamamoto Y, Ono H, Ueda A, Shimamura M, Nishimura K, Hazato T. Spinorphin as an endogenous inhibitor of enkephalindegrading enzymes: roles in pain and inflammation. Curr Protein Pept Sci 2002; 3(6): 587-99.
71. Yamamoto Y, Hashimoto J, Shimamura M, Yamaguchi T, Hazato T. Characterization of tynorphin, a potent endogenous inhibitor of dipeptidyl peptidaseIII. Peptides 2000; 21(4): 503-508.
72. Hola-Jamriska L, Dalton JP, Aaskov J and Brindley P. Dipeptidyl peptidase I and III activities of adult schistosomes. Parasitol 1999; 118; 275-282.
73. Dhanda S, Singh H. Distribution of dipeptidylpeptidase III homologue in the brain and vital organs in goat (Capra hircus). Indian J Animal Sci 2010; 79 (9): 715-718.
74. Simaga S, Abramic M Osmak M, Babić D, Ilić-Forko J. Total tissue lactate dehydrogenase activity in endometrial carcinoma. Int J Gynecol Cancer 2008; 18(6):1272-1278.
75. Nobel F, Soleihac JM, Soroca-Lucas E, Turcaud S, Fournie-Zaluski MC, Roques BP. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats. J Pharmacol Exp Ther 1992; 261: 181-190.
76. Elisseeva YE, Kugaevskaya EV. Structure and Physiological Importance of Angiotensin Converting Enzyme Domains. Biochemistry (MOSCOW) Supplement series b: Biomedical Chemistry 2009; 3(3): 237-247.
77. Nowak W, Errasti AE, Armesto AR, Santín Velazque NL, Rothlin RP. Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway. Eur J Pharmacol 2011; 667(1-3): 271-7.
78. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 1998; 31: 912-917.
79. Leung D, Abbenante G, Fairlie DP. Protease Inhibitors: Current Status and Future Prospects. Journal of Medicinal Chemistry 2000; 43(3): 305-34.
80. Ehlers MRW, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc. Natl. Acad. Sci. USA 1989; 86(20): 7741-7745.
81. Hooper NM. in Zinc Metalloproteases in Health and Disease, Hooper, N.M., Ed., London: Taylor Francis, 1996; 1-21.
82. Toropygin IY, Kugaevskaya EV, Mirgorodskaya OA et al. The Ndomain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 231-239.
83. Van Esch JH, Tom B, Dive V et al. Selective angiotensinconverting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 2005; 45: 120-125.
84. Wei S, Segura S, Vendrell J et al. Identification and Characterization of Three Members of the Human Metallocarboxypeptidase Gene Family. J Biol Chem 2002; 277: 14954-14964.
85. White MC. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588-99.
86. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 2001; 7 (1): 17-24.
87. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl 2007; 2: 13-18.
88. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl 2007; 2: 25-30.
89. Lyons PJ, Callaway MB, Fricker LD. Characterization of Carboxypeptidase A6, an Extracellular Matrix Peptidase. J Biol Chem 2008: 283: 7054-7063.
90. Salzmann A, Guipponi M, Lyons PJ, et al. Carboxypeptidase A6 gene (CPA6) mutations in a recessive familial form of febrile seizures and temporal lobe epilepsy and in sporadic temporal lobe epilepsy. Hum Mutat 2011. doi: 10.1002/humu.21613.
91. Lyons PJ, Ma LH, Baker R, Fricker LD. Carboxypeptidase A6 in Zebrafish Development and Implications for VIth Cranial Nerve Pathfinding. PLoS One 2010; 5: 1-11.
92. Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K et al. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. European Journal of Pharmacology 2006; 531(1-3):151-9.
93. Boudinot E, Morin-Surun M, Foutz AS, Fournie-Zaluski MC, Roques BP, Denavit-Saubie M. Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration. Pain 2001; 90(1-2): 7-13.
94. Nieto MM, Wilson J, Walker J, et al. Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management. Neuropharmacology 2001; 41(4): 496-506.
95. Hutcheson DM, Subhan F, Pache DM, et al. Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties. Eur J Pharmacol 2000; 401(2): 197-204.
96. Guen LS, Nieto M, Canestrelli C et al. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone. Pain 2003; 104(1-2); 139-48.
97. Chen H, Noble F, Roques BP, Fournie-Zaluski MC. Long Lasting Antinociceptive Properties of Enkephalin Degrading Enzyme (NEP and APN) Inhibitor Prodrugs, J. Med. Chem 2001; 44; 523-3530.
98. Laurent S, Boutouyrie P, Azizi M et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension 2000; 35: 1148-53.
99. Fournie-Zaluski MC, Coulaud A, Bouboutou R et al. New Bidentates as Full Inhibitors of Enkephalin-Degrading Enzymes: Synthesis and Analgesic Properties, J Med Chem 1985; 28: 1158-1169.
100. Zozulya ANV, Kost OY, Sokolov MV et al. The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine 2001; 4: 315-317.
101. Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol. 1998; 83: 45-56.
102. Matsas R, Stephenson SL, Hryszko J, Kenny AJ, Turner AJ. The metabolism of neuropeptides. Phase separation of synaptic membrane preparations with Triton X-114 reveals the presence of aminopeptidase N. Biochem J 1985; 231: 445-44.